Cellyan Biotechnology(NASDAQ) HKPD

Cellyan Biotechnology Co., Ltd is an investment holding entity focused on the over-the-counter (OTC) pharmaceutical sector, primarily serving markets in Hong Kong and mainland China. The company specializes in the international sourcing and distribution of OTC medications, along with comprehensive e-commerce supply chain management.

Products and Services

• International sourcing and distribution of OTC medications
• Comprehensive e-commerce supply chain management
• Logistical support including customs clearance and drug registration

Growth Outlook

• Revenue of 6.3 million in Q4 2026, showing potential for growth
• Gross profit margin improved to 13% in Q2 2026
• Strong demand in the OTC market across Hong Kong and mainland China

Financial Highlights

• Trailing twelve months (TTM) revenue of 6.3 million in Q4 2026
• Current ratio of 3.86 indicates strong liquidity
• Net income of -1.3 million in Q4 2026, reflecting ongoing investment in growth

Cellyan Biotechnology Co., Ltd operates in a dynamic sector with significant growth potential. The company's focus on OTC pharmaceuticals positions it well to capitalize on increasing demand in the healthcare market. Recent financial data indicates a revenue of 6.3 million in the latest quarter, suggesting a solid foundation for future growth. The improvement in gross profit margin to 13% in Q2 2026 reflects operational efficiencies and effective cost management. With a current ratio of 3.86, the company demonstrates strong liquidity, which is crucial for navigating the competitive landscape. Despite reporting a net income loss in Q4 2026, the ongoing investments in growth strategies highlight a commitment to long-term success. Overall, Cellyan Biotechnology presents an intriguing opportunity for investors interested in the healthcare sector.